Enanta Pharmaceuticals | ENTA - Operating Profit


Enanta Pharmaceuticals reported $-23.54M in Operating Profit for its fiscal quarter ending in December of 2024.





Operating Profit Change Date
AbbVie USD 4.73B 1.08B Mar/2026
Amgen USD 3.83B 130M Mar/2026
Anika Therapeutics USD 646K 3.88M Dec/2025
Arrowhead Research USD -141.26M 182.07M Mar/2026
AstraZeneca USD 7.11B 4.14B Mar/2026
BioCryst Pharmaceuticals USD 260.38M 230.79M Dec/2025
Biogen USD 514.3M 128.8M Mar/2026
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
Enanta Pharmaceuticals USD -23.54M 98.15M Dec/2024
Gilead Sciences USD 2.68B 284M Mar/2026
GlaxoSmithKline GBP 2.29B 856M Mar/2026
Halozyme Therapeutics USD -61.77M 26.64M Mar/2026
Heron Therapeutics USD 38K 3.83M Dec/2025
Immunic USD -23.33M 2.67M Dec/2025
Incyte USD 324.17M 59.7M Mar/2026
Insmed USD -200.28M 49.43M Mar/2026
Ionis Pharmaceuticals USD -118M 97M Mar/2026
J&J USD 6.62B 1.03B Mar/2026
Karyopharm Therapeutics USD -17.84M 13.44M Dec/2025
Ligand Pharmaceuticals USD 60.33M 40.29M Mar/2026
Merck USD -1.88B 8.12B Mar/2026
Neurocrine Biosciences USD 214.6M 13.3M Mar/2026
Novartis USD 4.24B 171M Mar/2026
Novavax USD 20.94M 100.32M Dec/2025
Pfizer USD 4.99B 340M Mar/2026
PTC Therapeutics USD 45.89M 127.51M Mar/2026
Roche Holding CHF 9.56B 3.8B Dec/2025
Sarepta Therapeutics USD 358.43M 768.52M Mar/2026
Vertex Pharmaceuticals USD 1.14B 124.5M Mar/2026